Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    The Case of Concurrent Therapy Concerns
    Treatment side effects
    The Case of Concurrent Therapy Concerns
    December 18, 2020
    In a World Where You Can Be Anything, Be Kind
    Nurse staffing
    In a World Where You Can Be Anything, Be Kind
    December 11, 2020
    Nursing Innovation Links Rural Facilities to Resources and Experts to Provide High-Quality Care Across the Country
    Access to cancer care
    Nursing Innovation Links Rural Facilities to Resources and Experts to Provide High-Quality Care Across the Country
    December 04, 2020
    Why All Oncology Nurses Should Be Environmentalists
    Oncology nurse influence
    Why All Oncology Nurses Should Be Environmentalists
    November 27, 2020
    ELNEC Milestone Marks Transformation of EOL Care for Countless Patients With Cancer
    Oncology nurse education
    ELNEC Milestone Marks Transformation of EOL Care for Countless Patients With Cancer
    November 20, 2020
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Oncology clinical trials

    FDA Approves Osimertinib as Adjuvant Therapy for NSCLC With EGFR Mutations
    U.S. Food and Drug Administration (FDA)

    FDA Approves Osimertinib as Adjuvant Therapy for NSCLC With EGFR Mutations

    On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved osimertinib (Tagrisso®) as adjuvant therapy after tumor resection for patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations, as detected by an FDA-approved test. 

    December 21, 2020
    Telegenetic Counseling Bridges Geographic Barriers and Minimizes Distress
    Research

    Telegenetic Counseling Bridges Geographic Barriers and Minimizes Distress

    Our 2009–2014 study, Bridging Geographic Barriers: Remote Cancer Genetics Counseling for Rural Women, also known as the REACH Project (Risk Education and Assessment for Cancer Heredity), was the first randomized, noninferiority trial of telephone-based BRCA1 and BRCA2 counseling and testing that used a population-based traceback approach to identify and counsel both rural and urban women who were at increased risk for hereditary breast and ovarian cancer but had not received genetic counseling or testing.

    December 10, 2020
    Study Links HPV Vaccine to Reduced Rates of Cervical Cancer
    Research

    Study Links HPV Vaccine to Reduced Rates of Cervical Cancer

    Cervical cancer rates have dropped more than 90% among women who received the human papillomavirus (HPV) vaccine, according to the results of a Swedish study published in the New England Journal of Medicine. Global health leaders are calling it a milestone study. 

    October 23, 2020
    Radiation Clinical Trials Must Evolve to Include Patient-Reported Outcomes
    Radiation therapy

    Radiation Clinical Trials Must Evolve to Include Patient-Reported Outcomes

    Prostate cancer is one of the most common cancers treated with radiotherapy (RT). Conventional RT for low-risk patients usually involves 40–45 treatments given over eight or nine weeks. Several studies suggest that hypofractionated RT—fewer treatments but with a higher dose per treatment—may produce a similar survival benefit. When two treatments have similar survival outcomes, the decision process looks at symptom profiles, quality of life, and cost.

    October 14, 2020
    The Case of the HPV-Positive Perk
    Clinical practice

    The Case of the HPV-Positive Perk

    Warren is a 50-year-old man recently diagnosed with human papillomavirus (HPV)-positive oropharyngeal cancer. He and his wife meet with a radiation oncologist and develop a plan of care. Lisa, the radiation oncology nurse, meets with the couple to provide education and answer questions. Darren tells her that two of his “hard living” uncles died from head and neck cancer and the treatment was horrible. He says, “I’ve only had two sexual partners and never smoked—is this cancer really worth treating?”

    July 21, 2020
    Prostate Cancer Clinical Trials Don’t Reflect Racial Diversity—And It’s Getting Worse Over Time
    Cancer research

    Prostate Cancer Clinical Trials Don’t Reflect Racial Diversity—And It’s Getting Worse Over Time

    More than 96% of participants in prostate cancer clinical trials are non-Hispanic white men even though non-Hispanic black men represent 22% of prostate cancer diagnoses, researchers reported in Cancer Epidemiology, Biomarkers, and Prevention. Even more critical, enrollment rates of black or African American men have been declining since 1995.

    July 08, 2020
    Geographic Disparities Affect Clinical Trials Participation for Minorities
    Cancer health disparities

    Geographic Disparities Affect Clinical Trials Participation for Minorities

    Clinical trials are a vital part of moving cancer care into the future. Enrollment and participation provide patients with cutting-edge treatments and build the knowledge base for clinicians to offer the best possible care available. Patients who enroll in clinical trials receive a high quality of care, increased surveillance, and a greater adherence to treatment protocols because of the nature of scientific study. However, Latino and African American participation in clinical trials is low compared to their representation in the U.S. population.  

    April 07, 2020
    FDA Issues Guidance for Conducting Clinical Trials During COVID-19
    U.S. Food and Drug Administration (FDA)

    FDA Issues Guidance for Conducting Clinical Trials During COVID-19

    On March 18, 2020, the U.S. Food and Drug Administration (FDA) issued a guidance for industry, investigators, and institutional review boards conducting clinical trials during the COVID-19 coronavirus pandemic in recognition that it may affect the conduct of clinical trials of medical products, including drugs, devices, and biologic products.

    March 25, 2020
    Clinical Trial Participants Average  6.5 Years Younger Than Actual Cancer Populations
    Research

    Clinical Trial Participants Average 6.5 Years Younger Than Actual Cancer Populations

    For the four most common cancer sites (breast, prostate, colorectal, and lung cancer), the median age of patients in clinical trials is an average of 6.5 years younger than the median age of patients diagnosed with that cancer. And the age disparity is worsening, researchers reported in JAMA Oncology. 

    August 07, 2019
    New CAR T-Cell Targets Show Safe Results in Early Clinical Trials
    Research

    New CAR T-Cell Targets Show Safe Results in Early Clinical Trials

    Findings from two phase I clinical trials presented at the American Association for Cancer Research 2019 annual meeting indicate that targeting CAR T cells against mesothelin for advanced solid tumors and HER2 for advanced sarcoma is safe and shows clinical antitumor activity.

    June 26, 2019
    ONS Congress

    Nurses Must Be Pharmacovigilant With Emerging Cancer Treatments

    The field of cancer care is changing and evolving like never before. In 2018, the U.S. Food and Drug Administration (FDA) approved a number of new biosimilars, targeted agents, and agents that target certain mutations regardless of tumor site. New requirements for accreditation and reimbursement mean oncology nurses are being used in a growing number of new or developing roles including navigation and survivorship. On Thursday, April 11, 2019, Kathleen Wiley, RN, MSN, AOCNS®, addressed these emerging trends and more in a clinical chat at the ONS 44th Annual Congress in Anaheim, CA.

    April 11, 2019
    Drug Pricing Talks; Clinical Trial Barriers; Survivorship Challenges
    Prescription medication

    Drug Pricing Talks; Clinical Trial Barriers; Survivorship Challenges

    Rising prescription medication costs has been a major focus area for both the Trump administration and the 116th Congress. In January 2019, both the House and Senate committees of jurisdiction held public hearings on soaring drug costs. Despite constant media attention and mounting pressure from government officials, no pharmaceutical company executives chose to testify. Congress threatened to subpoena the industry if it happened again.

    February 25, 2019
    VA and NCI Collaborate on Access to Cancer Clinical Trials
    National Cancer Institute (NCI)

    VA and NCI Collaborate on Access to Cancer Clinical Trials

    A new cross-government program is underway to improve veterans’ access to clinical cancer trials. Together with the National Cancer Institute (NCI), the Department of Veterans Affairs (VA) Interagency Group to Accelerate Trials Enrollment launched in 12 VA facilities in summer 2018.

    September 12, 2018
    How Is CTCAE Improving Research and Patient Care?
    Oncology clinical trials

    How Is CTCAE Improving Research and Patient Care?

    The Common Terminology Criteria for Adverse Events (CTCAE) is a list of adverse event (AE) terms most often encountered in oncology. It’s been in ongoing development since the 1980s and was previously referred to as the Common Toxicity Criteria. Through continual development and support from the National Cancer Institute’s Cancer Therapy Evaluation Program, CTCAE aids in the documentation and analysis of adverse events in oncology-related clinical trials.  

    August 01, 2018
    Patient on a Clinical Trial Needs to Visit the Dentist
    Oncology clinical trials

    What Would You Say if Your Patient on a Clinical Trial Needs to Visit the Dentist?

    One of your patients is enrolled in a clinical trial and is scheduled to receive an investigational drug today. She reports a cracked tooth and asks if it’s okay to get dental work. What should you tell her? 

    A. To Set up an appointment with her dentist between treatment cycles. 

    B. To check with her research team before setting up a dental appointment. 

    C. Not to have any dental work done since she’s on a clinical trial.  

    D. Have her tooth fixed right away and let the research team know if you have any problems. 

    July 17, 2018
    Consider a Role in Clinical Trials Research as an Evolution of Your Nursing Career
    Oncology clinical trials

    Consider a Role in Clinical Trials Research as an Evolution of Your Nursing Career

    Nurses can do it all. After all, the often-unsung heroes of health care use their unique skills to positively impact patients and their families in more ways than most people can ever imagine. Unfortunately, role confusion and a lack of awareness of a vital specialty have led to a dire need of nurses in clinical trials.

    July 13, 2018
    Communication, Organization Are Top Drivers of Oral Adherence in Clinical Trials
    Oral adherence

    Communication, Organization Are Top Drivers of Oral Adherence in Clinical Trials

    Oncology nurses know the challenges of patient adherence to oral cancer therapies. Every dose a patient misses can affect their outcomes and chance of survival. But in clinical trials, oral adherence has even broader implications: when a study is evaluating the efficacy of a drug, it depends on study participants taking it exactly as the trial outlines.

    July 10, 2018
    What You Need to Know About Obtaining Informed Consent
    Oncology clinical trials

    What You Need to Know About Obtaining Informed Consent

    Informed consent is a comprehensive process as opposed to a check mark on a list of tasks to complete prior to starting cancer therapy. The American Society of Clinical Oncology/ONS Chemotherapy Administration Safety Standards explain that informed consent provides a patient with “sufficient information about the disease diagnosis and treatment options so that the individual can make a reasonable decision about treatment on the basis of an understanding of the potential risks and anticipated benefits of the treatment.”

    May 28, 2018
    Oncology clinical trials

    Geographic Health Disparities Affect Access to Clinical Trials

    Geographic location impacts life expectancy and even cancer care. Marylynn Ostrowski Ireland, PhD, of Viability, Inc., and Deborah Watkins Bruner, PhD, RN, FAAN, of Emory University in Atlanta, GA, discussed geographic health disparities during a session at the 43rd Annual Congress in Washington, DC.

    May 19, 2018
    The Case of the Pain Paradox: Follow-Up and Clinical Trial
    Pain management

    The Case of the Pain Paradox: Follow-Up and Clinical Trial

    The January 2018 case study introduced Vince, a 55-year-old man receiving chemotherapy and radiation for recurrent bladder cancer. He suffers from chronic back pain because of spinal stenosis and has been on opioid therapy for nearly two years.

    March 20, 2018
    How the FDA Provides New Approaches to Old Problems
    U.S. Food and Drug Administration (FDA)

    How the FDA Provides New Approaches to Old Problems

    Every quadrennial presidential cycle, as the newly elected leader moves into the Oval Office, he selects a core group of advisors who are philosophically aligned and eager to make changes in the federal government’s process. However, this is often not as simple as the new administration believes.

    November 20, 2017
    Sheila Prindiville
    Oncology clinical trials

    How Do You Find Clinical Trials Through the NCI’s Advanced Clinical Trials Search?

    As part of the National Cancer Moonshot Initiative and in collaboration with the Presidential Innovation Fellows, the National Cancer Institute (NCI) developed and launched a new website in 2016. It provides user-friendly access to the repository of abstracts of cancer clinical trials that NCI supported.

    September 05, 2017
    oncology clinical trial nurses impact cancer care
    Oncology clinical trials

    Oncology Nurses Drive Change In Cancer Care With Clinical Trials

    Clinical trials are responsible for discovering new treatments for cancer as well as the continued evolution of standards of care in clinical practice. Nationally, less than 5% of all eligible adult patients with cancer enroll in clinical trials. Additionally, it takes a drug an average of six to eight years from when it is first introduced in trials to become fully available to all patients who could benefit from it.

    September 05, 2017
    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Halts Two Clinical Trials Evaluating Pembrolizumab in Patients With Multiple Myeloma

    On August 31, 2017, based on data from two recently halted clinical trials, the U.S. Food and Drug Administration (FDA) is issuing a statement to inform the public, healthcare professionals, and oncology clinical investigators about the risks associated with the use of Keytruda (pembrolizumab) in combination with dexamethasone and an immunomodulatory agent (lenalidomide or pomalidomide) for the treatment of patients with multiple myeloma. Keytruda (pembrolizumab) is not approved for treatment of multiple myeloma.

    August 31, 2017
    Patients Randomized to Cancer Clinical Trials
    National Cancer Institute (NCI)

    How Are Patients Randomized to Cancer Clinical Trials?

    Before any new treatment or approach is used with people in clinical trials, researchers work to understand its effects on cancer cells in the lab and in animals. Researchers design cancer clinical trials to test new ways to treat, detect, diagnose, and prevent cancer, and manage symptoms of cancer and side effects from treatment.

    August 10, 2017
    Cancer Clinical Trials
    Oncology clinical trials

    How One Institution Improved Accrual to Cancer Clinical Trials

    One of the key factors to a cancer clinical trial’s success is the ability to enroll an adequate number of patients in an appropriate timeframe. Identifying barriers to slow accrual and ways to address them can help researchers and nurse scientists make big steps in the fight against cancer in the era of the National Cancer Moonshot Initiative.

    May 17, 2017
    ONS Congress

    How Oncology Nurses Can Contribute to Immunotherapy Clinical Trials

    Using the human immune system to target cancer has made tremendous strides in recent years. Jaruska Naidoo, MBBCh, from the Sidney Kimmel Comprehensive Cancer Center, and Joanne Riemer, RN, BSN, from Johns Hopkins University, discussed the progress made in immunotherapy and how nurses play a role in clinical trials during a session at the 42nd Annual Congress in Denver, CO.

    May 06, 2017
    Oncology clinical trials

    Why Does the FDA Place Clinical Holds on Investigational New Drug Clinical Trials?

    You have a patient with cancer who is participating in a clinical trial. The patient has just been told that the trial has been placed on a clinical hold. What does that mean? What should you say to your patient?
    December 06, 2016
    Cancer moonshot

    Vice President Announces Strategic Goals, New Partnerships for Cancer Moonshot

    On October 17, 2016, Vice President Joe Biden addressed President Obama and the rest of the United States as he presented the National Cancer Moonshot taskforce’s report of the work that’s been accomplished since its inception in January 2016. The report highlights a number of strategic initiatives, including the 10 recommended areas of scientific advancement the Blue Ribbon Panel identified in September.
    October 19, 2016
    Health Policy

    HHS Requires More Information on Clinical Trials to Be Public

    In a move to make government sponsored clinical trials publicly known and easily found, the Department of Health and Human Services (HHS) announced a new process for submitting and releasing clinical trials on the government's new clinical trials website.
    October 06, 2016
    Cancer treatments

    Poliovirus May Be Key to Treating Glioblastoma

    A phase I study has shown that a small group of patients with recurrent glioblastoma who received treatment with a modified form of poliovirus showed survival improvement over historical controls. The findings, which were not peer reviewed, were presented at the 2016 American Society of Clinical Oncology annual meeting.
    August 16, 2016
    Access to cancer care

    Oncology Nurses Have Important Roles in Clinical Trial Access and Enrollment

    When President Obama announced the National Cancer Moonshot Initiative during his State of the Union address in January 2016, he set lofty goals for oncology professionals. One of those goals called for increased access to and participation in clinical trials. Clinical trial data are integral in getting cutting-edge treatments to market, where they can help improve cancer care. However, many patients aren’t fully educated about the efficacy of these new forms of treatment and what these trials entail.
    May 27, 2016
    Clinical practice

    The Case of the Clinical Trial Candidate

    Joe is a 54-year-old man with metastatic colorectal cancer who has been receiving treatment at the cancer center for the past three years. The cancer center has a stage II trial, which is investigating nintedanib plus capecitabine for patients with refractory colorectal cancer. What would you do?
    April 19, 2016
    Oncology nurses at local community cancer center
    Cancer research

    Academic-Community Partnerships

    The news is peppered with stories of the latest studies of new ways to treat or prevent cancer. What do most of those studies have in common? The majority were conducted in large, academic medical centers, leading many to believe that those institutions are where most patients with cancer are receiving their care.
    April 05, 2016
    Cancer moonshot

    National Cancer Moonshot Initiative Could Learn From Open-Source Data Ideas

    At the 2016 State of the Union Address, President Obama announced a commitment to eliminating cancer by 2020. The “moonshot” is to be led by Vice President Joe Biden, who lost his son to a brain tumor last May. In his statement, Biden acknowledges that there are currently many barriers to cancer research and finding a cure. The Cancer Moonshot will need to come at the problem from many angles in order to be effectual.
    April 01, 2016
    Oncology clinical trials

    More Research Is Needed for Adolescent and Young Adult Cancers

    Many young adults are just coming into their own through their teenage years and into their 20s. They’re attending college or entering the workforce, they’re beginning to form serious relationships, and they’re often coming to terms with what it means to be an adult. Unfortunately, this age group is not immune to cancer diagnoses. In fact, according to the National Cancer Institute (NCI), more than 70,000 adolescent and young adult (AYA) cancer diagnoses happen each year.
    March 31, 2016
    Research on oncology drugs
    Oncology clinical trials

    Innovative Clinical Trial Designs Lead to New Drug Approvals

    The U.S. Food and Drug Administration uses clinical trial results to determine whether to approve a new drug for marketing in the United States. Clinical trials are designed to test the safety and efficacy of a drug or combination of drugs to treat a specific type of cancer, such as breast or lung cancer.
    March 01, 2016
    Combination Vaccine and Docetaxel for Metastatic Breast Cancer
    Breast cancer

    Combination Vaccine and Docetaxel May Improve Survival for Metastatic Breast Cancer

    Results from an open-label, phase II, randomized clinical trial comparing docetaxel alone or in combination with PANVAC, a viral-vector cancer vaccine, in patients with metastatic breast cancer suggest that the vaccine may have some clinical benefit.
    February 16, 2016
    Shared decision making process in cancer clinical trials
    Oncology clinical trials

    Research Helps Guide Shared Decision Making in Cancer Clinical Trials

    At the onset, patients diagnosed with cancer can feel a loss of control. Research has shown that when patients and providers participate in shared decision making (SDM), both parties find greater satisfaction in the overall decision and adherence to the treatment plan improves.
    February 02, 2016
    Oncology clinical trials

    Research Helps Guide Shared Decision Making in Clinical Trials

    January 26, 2016
    Oncology clinical trials

    Better Understand Oncology Clinical Trial Data With This Quick Reference Guide

    Oncology clinical trial results form the backbone of oncology medicine. How well do you understand the tables, plots, and statistics generated as a result of clinical research? During the recent ONS Congress, many presenters displayed new study data using charts with naturalistic names, such as waterfall, skyline, forest, and spider plots.
    May 12, 2014
    Research

    What Should Oncology Nurses Know About Type I and Type II Errors in a Clinical Study?

    January 07, 2014
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    • Oncology nurse influence
    View All Topics
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2021 Oncology Nursing Society
     
    Back to Top ▲